Suspendido

PIF-SET1Preimplantation Factor (PIF): Prognostic Value of a Non-invasive Embryo Viability Biomarker Detection in Culture Media Followed by Single Embryo Transfer - Correlation With Live Birth.

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está recopilando

Colección de datos

Recopilados desde hoy en adelante - Prospectivo
Sin Muestra de ADN
Quiénes están siendo reclutados

Enfermedades Urogenitales+1

+ Enfermedades Urogenitales Femeninas y Complicaciones del Embarazo

+ Complicaciones del embarazo

A partir de 18 años
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Casos y Controles

Examen de las características de personas con una enfermedad para identificar factores genéticos o ambientales que contribuyen a la condición.
Observacional
Inicio del estudio: septiembre de 2012
Ver detalles del protocolo

Resumen

Patrocinador PrincipalBioIncept LLC
Última actualización: 4 de marzo de 2013
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 1 de septiembre de 2012

Fecha en la que se inscribió al primer participante.

The aim of the proposed project is to investigate a non invasive biomarker, PIF (PreImplantation Factor), a 15amino acid peptide (MVRIKPGSANKPSDD) secreted only by viable embryos and placenta (Stamakin et al. RBE 2011). PIF positive embryos will be able to grow to blastocyst stage and PIF levels could be a marker of progressive pregnancy. We will measure PIF levels in IVF culture media before embryo transfer to correlate IVF pregnancy with PIF levels. Our objective will be to define PIF as a biomarker for viable embryos in order to increase IVF success rates following SET. PIF levels will be retrospectively evaluated after 500 SET. Our four reproductive centres perform about 200 SET per year and more than 500 in vitro fertilizations. For women selected for a SET, PIF levels will be evaluated in all embryo culture media, and later at one and two weeks after each transfer of fresh or thawed frozen embryos in maternal serum. Embryo transfers will be done blinded to PIF results. SET or MET will be based on clinical evaluation and conventional embryo criteria. For these women, PIF will be also evaluated and compared with βhCG level on maternal serum. PIF assessment will be performed using specific antibody marked with a fluorescent dye, in Luminex reader. Specific Aim One will allow us to evaluate: PIF predictive value on implantation rate PIF predictive value on pregnancy Methodology All women will be fully informed and a written consent to participate in the study will be duly obtained. In vitro procedure Oocytes were retrieved after natural cycle or after ovarian hyperstimulation which will be performed using the modified long protocol. Collected oocytes will be fertilized by classic IVF or ICSI. Fertilization will be confirmed by the observation of 2 pronuclei and two polar bodies, after 16-18 hours. Fertilized oocytes will be cultured in 60μl of culture media under oil. Embryo transfer will be performed 72 hours after IVF or ICSI procedure (at day D3) without PIF result. Before transfer, embryo quality will be scored according to number of cells, kinetic of cleavage and fragmentation rate. For women who will have a SET, according to clinical criteria (Age, FSH level, etc…) remaining good quality embryos will be frozen and thawed after uterine preparation in further attempts. All remaining culture supernatants (50-60μl) will be collected, transferred to 8-strip 0.2ml tubes and stored to -80C until they will test for PIF (M) Maternal serum retrieval Maternal serum will be collected: before oocytes retrieval in course of a serum control of ovarian hyperstimulation (S0) one week after transfer (S1) two week after transfer during serial human β-chorionic gonadotrophin measurements (S2) PIF level evaluation PIF levels in culture supernatants and in maternal serum will be measured retrospectively, using a bead-based competitive assay for use in the Luminex 200 IS system. Results presented as median fluorescence intensity (MFI). PIF levels were derived from standard curve using a 5-parameter logistics curve. The threshold of detection was established by measuring the background from culture media or maternal serum alone, using mean+2SD as a cut off (18.7ng/ml). Analysis Correlate PIF detection in embryo serum with embryo viability. Results of PIF detection in embryo supernatants will be correlated with pregnancy outcome. Comparison with embryo selection by PIF+ vs PIF- embryos, using morphology alone, and by morphology combined with PIF presence. Comparisons between groups will be performed using chi-square analysis and p<0.05 will be considered as statistically significant. Inclusion/exclusion criteria Inclusion criteria: All women included in our centers for classical IVF or ICSI, who will sign the written consent to participate in the study. PIF level evaluation in culture media (M) and pregnancy prognosis (S1 and S2) will be done only for women with SET. Exclusion criteria Women who will refuse to participate in the program. Planned assessments (time and events table) The overall project is planned to be carried out through five steps work plan in which we will investigate the use of PIF as a biomarker for better embryo selection (only women with SET will be included) and as a early pregnancy marker in maternal serum.

NCT01803893
Patrocinador PrincipalBioIncept LLC
Última actualización: 4 de marzo de 2013
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 500 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Casos y Controles

Estos estudios comparan personas que tienen una enfermedad (casos) con quienes no la tienen (controles), analizando exposiciones o factores de riesgo pasados para identificar posibles causas.


Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Mujer

Sexo biológico de los participantes elegibles para inscribirse.

A partir de 18 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

Enfermedades UrogenitalesEnfermedades Urogenitales Femeninas y Complicaciones del EmbarazoComplicaciones del embarazoAborto Espontáneo

Criterios

Inclusion criteria: All women included in our centers for classical IVF or ICSI, who will sign the written consent to participate in the study. PIF level evaluation in culture media (M) and pregnancy prognosis (S1 and S2) will be done only for women with SET. Exclusion criteria Women who will refuse to participate in the program.

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

2 grupos de intervención están designados en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene 5 ubicaciones

Yale Women and Children's Center for Blood Disorders & Yale Fertility Center

New Haven, United StatesAbrir Yale Women and Children's Center for Blood Disorders & Yale Fertility Center en Google Maps

Poissy St Germain Hospital

Poissy, France

Lab Clement - Seine St. Denis Hospital, Le Blanc Mesnil

Paris, France

Versailles St. Quentin University

Poissy, France
Suspendido5 Centros de Estudio